This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Merck Sharp + Dohme Corp.. Active years: 2013.
Company Filing History:
Years Active: 2013
Title: Cyrille Sur: Innovator in Alzheimer's Disease Diagnostics
Introduction
Cyrille Sur, an accomplished inventor based in Harleysville, PA, has made significant contributions to the field of medical diagnostics, particularly in Alzheimer's disease. He holds a patent for his innovative work in developing novel amyloid binding compounds that have the potential to transform how we diagnose and understand Alzheimer's.
Latest Patents
Cyrille Sur's patent, titled "Substituted azabenzoxazoles," focuses on new amyloid binding compounds and the methods for assessing their ability to influence amyloid plaque levels in living patients. This innovative invention utilizes the compounds as tracers in positron emission tomography (PET) imaging, enabling researchers and clinicians to study amyloid deposits in the brain in vivo. This groundbreaking approach not only aids in the diagnosis of Alzheimer's disease but also provides a means to measure the clinical efficacy of therapeutic agents for the condition.
Career Highlights
Cyrille Sur works at Merck Sharp & Dohme Corporation, a leading company in the pharmaceutical industry that focuses on healthcare solutions. His career is marked by his dedication to advancing medical research and improving patient outcomes through innovative inventions and methodologies. With a patent to his name, Cyrille has established himself as a key player in the realm of Alzheimer’s diagnostics.
Collaborations
Throughout his career, Cyrille has had the opportunity to collaborate with esteemed colleagues such as James C. Barrow and Scott T. Harrison. These collaborations have allowed him to further refine his inventions and contribute to the collective goal of enhancing our understanding of Alzheimer’s disease and improving diagnostic techniques.
Conclusion
Cyrille Sur exemplifies the spirit of innovation in the medical field with his groundbreaking patent on amyloid binding compounds. His work has the potential not only to advance Alzheimer's disease diagnostics but also to pave the way for future research and therapeutic development. As the need for effective diagnostic tools increases, Cyrille’s contributions will undoubtedly have a lasting impact on healthcare and patient care.